Corbin Burnes' $210 million, 6-year deal with D-backs includes $64 million deferred through 2036

NEW YORK (AP) — Right-hander Corbin Burnes' $210 million, six-year contract with the Arizona Diamondbacks includes $64 million in deferred payments due from 2031-36, according to details obtained by The Associated Press.

Burnes gets a $10 million signing bonus payable within 30 days of the deal's approval by the commissioner's office and salaries of $30 million each in 2025 and 2026 and of $35 million in each of the following four seasons.

His deal, announced Monday and the largest in Diamondbacks history, includes $10 million in deferred money in each of the first two years and $11 million in each of the next four.

Burnes, the 2021 NL Cy Young Award winner and a four-time All-Star, has the right to opt out after the 2026 season.

If he does not opt out, the deferred money is payable $10 million each on Nov. 1 in 2031 and '32, and $11 million each Nov. 1 from 2033-36.

If Burnes does opt out, the deferred money is payable in $10 million installments on Nov. 1 in 2027 and 2028.

He has a full no-trade provision through March 31, 2027. If he does not opt out, he can specify by each March 15 starting in 2027 a list of 14 teams he can't be traded to without his consent.

Burnes would get $250,000 for winning a Cy Young Award, $150,000 for finishing second in the voting, $100,000 for third, $75,000 for fourth and $50,000 for fifth.

He would earn $50,000 each for All-Star election or selection, winning a Gold Glove, World Series MVP, League Championship Series MVP or finishing first or second on the All-MLB team.

Arizona agreed to give Burnes four premium season tickets in a best-available location at no cost for all regular-season, postseason and spring training games. Burnes is allowed to purchase up two additional tickets adjacent to the team-provided seats.

Burnes gets a hotel suite on road trips and agreed to donate 1% of his salary and signing bonus to the team charitable foundation.

He joins a starting rotation projected to include Zac Gallen, Merrill Kelly, Brandon Pfaadt and Eduardo Rodríguez.

Burnes, who turned 30 in October, was 15-9 with a 2.92 ERA last year for Baltimore, which acquired him from Milwaukee in a February trade. He is 60-36 with a 3.19 ERA in seven seasons for the Brewers and Orioles.

AP MLB: https://apnews.com/hub/mlb

FILE - Baltimore Orioles' Corbin Burnes pitches during the first inning of a baseball game against New York Yankees, Thursday, Sept. 26, 2024, in New York. (AP Photo/Noah K. Murray, File)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Jan 12, 2026--

ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the region, ChemWerth has hired Chandrakanth Reddy as general sales manager of its India office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260111302280/en/

“The addition of a general sales manager in India signals our desire to grow our presence and customer base in the world’s most important generic pharmaceutical market,” said Pete Werth III, president, ChemWerth. “Chandrakanth will add tremendous value for our customers and contract manufacturing organizations (CMOs) in India.”

Reddy is a seasoned pharmaceutical professional with more than 16 years of experience spanning API sourcing, business development, market expansion and regulatory-driven commercial strategy. He has successfully led high-value markets across India, the Middle East, North Africa, Europe, and the United States, building strong customer partnerships and supporting sustainable revenue growth.

In his new role, Reddy will be responsible for leading ChemWerth’s sales strategy in India and strengthening regional customer relationships. He will also support the company’s focused initiative to roll out new generic APIs in the market, including fermentation, peptide and oncology injectable APIs.

“After reviewing ChemWerth’s strategic plan to unveil a strong pipeline of new generic fermentation, peptide and oncology injectable APIs for the Indian market, I knew that was something I wanted to be a part of,” said Reddy.

About ChemWerth, Inc.:

Established in 1982, ChemWerth is a full-service generic active pharmaceutical ingredient (API) development and supply company providing cGMP-quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India. For more information, please visit www.chemwerth.com.

Chandrakanth Reddy has joined ChemWerth, Inc., as general sales manager of its India office.